RecruitingSpecific Advanced Solid Tumors

Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.

Sponsor: Acrivon Therapeutics

You may qualify if…

✓ 1. Signed written informed consent.
✓ 2. Histologically or cytologically proven metastatic, recurrent or locally advanced selected solid tumors.
✓ 3. Must be willing to provide redacted pathology report.
✓ 4. Subjects should have received no more than 3 lines of systemic therapy for recurrent disease.
✓ 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months.
✓ 6. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST v1.1.
✓ 7. Adequate organ functions.
✓ 8. Must have progressed after prior line of treatment.

You may not qualify if…

✕ 1. Participants with known symptomatic brain metastases.
✕ 2. Participant had systemic therapy within 3 weeks prior to the first dose of study drug.
✕ 3. Participant had radiation therapy for curative intent within 4 weeks prior to the first dose of study drug.
✕ 4. Participant had palliative radiation therapy within 2 weeks prior to the first dose of study drug.
✕ 5. Women who are pregnant or lactating.